C

Caladrius Biosciences Inc
LSE:0HS8

Watchlist Manager
Caladrius Biosciences Inc
LSE:0HS8
Watchlist
Price: 1.955 USD -3.46%
Market Cap: 37.9m USD

P/E
Price to Earnings

-2
Current
-2.4
Median
24
Industry
Higher than median
Lower than industry value

The Price to Earnings (P/E) ratio shows how much investors are willing to pay for each dollar of a company’s earnings. It’s calculated by dividing the company’s market value by its net income.

P/E
-2
=
Market Cap
37.9m USD
/
Net Income
-18.9m USD
All Countries
Close
Earnings Growth PEG
US
C
Caladrius Biosciences Inc
LSE:0HS8
Average P/E: 195.9
Negative Multiple: -2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 126.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
167.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.1
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.3
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.9
9%
1.8
AU
CSL Ltd
ASX:CSL
19.5
11%
1.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 256.1
N/A N/A
NL
argenx SE
XBRU:ARGX
35.7
40%
0.9

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-2
2-Years Forward
P/E
-4.4
3-Years Forward
P/E
-6.4